Novo's
pioneering diabetes pill beats Victoza, Januvia in tests
Send a link to a friend
[June 21, 2018] COPENHAGEN
(Reuters) - Novo Nordisk's experimental diabetes pill, which it hopes
will transform the diabetes market, has proved superior to both Merck &
Co's Januvia and its own best-selling injectable treatment Victoza in
tests.
|
The positive results in the latest of a series of pivotal clinical
trials boost analysts' expectations that Novo's oral semaglutide
medicine could become a multibillion-dollar blockbuster. Novo shares
jumped more than 4 percent in early trade on Thursday.
The trial against Victoza, a once-daily injection, met the primary
endpoint of similar blood sugar reduction but was also superior on
weight loss, Novo said in a statement late on Wednesday.
"This data is important, as it positions oral-sema as at least as
good as the market leading injectable GLP-1," said Deutsche Bank
analysts.

The once-daily pill belongs to a blockbuster class of treatments
known as GLP-1s that stimulate insulin production, the first of
which were derived from the venomous bite of North America's Gila
monster lizard. So far, all have been injections.
Deutsche believes oral semaglutide could eventually sell more than
$5 billion a year and allow Novo to grow sales in the high-margin
GLP-1 diabetes segment for years to come, with the new product
potentially priced closer to expensive injections than cheaper
diabetes pills.
[to top of second column] |

Analysts from Bernstein also said the outcome was stronger than
anticipated.
The outcome of the trial against Merck's Januvia, an oral medication
known chemically as sitagliptin, showed Novo's new drug was superior
in demonstrating reductions in both long-term blood sugar level and
weight, Novo said.
The success of oral semaglutide in the Phase III trials is a fillip
for a medicine seen as important for ensuring the group's long-term
growth in a highly competitive diabetes market. It follows earlier
results from other Phase III studies that have also been positive.
(Reporting by Stine Jacobsen and Ben Hirschler; Editing by Keith
Weir)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |